• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

NVentures Invests in Genesis Therapeutics’ AI Platform for Drug Development

by Syed Hamza Sohail 11/13/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know:

– Genesis Therapeutics, a company pioneering artificial intelligence (AI) technologies to create breakthrough medicines for patients, announced today a further equity investment from NVentures, NVIDIA’s venture capital arm.

– This investment is in addition to NVentures’ participation in the company’s $200 million Series B financing in August 2023.

Genesis Therapeutics Partners with NVIDIA to Advance AI-Driven Drug Discovery

Genesis Therapeutics, an AI-focused biotechnology company headquartered in Burlingame, CA, is revolutionizing small molecule drug discovery through its proprietary generative and predictive AI platform, **GEMS (Genesis Exploration of Molecular Space)**. GEMS integrates cutting-edge AI methodologies, including language models, diffusion models, and physical machine learning (ML) simulations, to generate and optimize molecules targeting complex biological structures.

Key Highlights of Genesis Therapeutics:

– Advanced AI Integration:

  – Utilizes proprietary AI methods such as language models, diffusion models, and physical ML simulations.

  – Enables the generation and optimization of molecules for intricate and high-impact targets.

– Significant Funding and Growth:

  – Successfully raised over $300 million from leading investors in the life sciences, technology, and AI sectors.

  – Developing a robust therapeutic pipeline addressing a variety of high-impact biological targets.

– Strategic Collaboration with NVIDIA:

  – Partnering with NVIDIA to enhance the efficiency of the GEMS platform.

  – Leveraging NVIDIA’s expertise to optimize computation for several neural network architectures crucial to drug discovery.

  – Focused on optimizing equivariant neural networks, which are essential for handling 3D geometric data such as protein and small molecule structures.

– Integrated Operations:

  – Headquartered in Burlingame, CA, with a fully integrated laboratory in San Diego.

  – Ensures seamless synergy between AI-driven research and laboratory-based experimental validation.

Through this collaboration, Genesis Therapeutics aims to accelerate its AI platform, making computational processes more efficient and enhancing the precision of drug discovery efforts. By leveraging NVIDIA’s technological expertise, Genesis is poised to advance its mission of developing novel therapeutics with greater accuracy and speed, ultimately addressing critical challenges in the biotechnology landscape.

“We look forward to combining our expertise and resources with NVIDIA’s to help realize our vision of harnessing AI to generate breakthrough therapies for diseases with high unmet need,” said Evan Feinberg, Ph.D., founder and CEO of Genesis. “Addressing previously undruggable targets to create new medicines requires pioneering algorithms for drug discovery and fundamental infrastructure innovation. Working with NVIDIA, we will further the capabilities of our field-leading physical AI platform for structure-driven drug design.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Artificial Intelligence, Drug Discovery

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Interview

Reach7 Diabetes Studios Founder Chun Yong on Reimagining Chronic Care with a Concierge Medical Model

Most-Read

HHS Finalizes HTI-4 Rule: Prior Authorization & E-Prescribing Interoperability

HHS Finalizes HTI-4 Rule: Prior Authorization & E-Prescribing Interoperability

Meaningful Use Penalties_Meaningful Use_Partial Code Free_Senators Urge CMS to Establish Clear Metrics for ICD-10 Testing

CMS Finalizes TEAM Model: A New Era of Value-Based Surgical Care

White House Event Unveils CMS Health Tech Ecosystem Initiative

White House Event Unveils CMS Health Tech Ecosystem Initiative

Digital Health Faces Q2'25 Pullback: Funding Falls to 5-Year Low, But AI Dominates and $1B+ IPOs Emerge

Healthcare Investment Shifts in 1H 2025: AI Remains a Bright Spot Amidst Fundraising Decline

Digital Health Faces Q2'25 Pullback: Funding Falls to 5-Year Low

Digital Health Faces Q2’25 Pullback: Funding Falls to 5-Year Low

Beyond the Hype: Building AI Systems in Healthcare Where Hallucinations Are Not an Option

Beyond the Hype: Building AI Systems in Healthcare Where Hallucinations Are Not an Option

Health IT Sector Navigates Policy Turbulence with Resilient M&A

Health IT’s New Chapter: IPOs Return, Resilient M&A, Valuations Rise in 1H 2025

PwC Report: US Medical Cost Trend to Remain Elevated at 8.5% in 2026

PwC Report: US Medical Cost Trend to Remain Elevated at 8.5% in 2026

Philips Launches ECG AI Marketplace, Partnering with Anumana to Enhance Cardiac Care with AI-Powered Diagnostics

Philips Launches ECG AI Marketplace, Partnering with Anumana to Enhance Cardiac Care with AI-Powered Diagnostics

WeightWatchers Emerges from Bankruptcy, Launches New Menopause Program

WeightWatchers Emerges from Bankruptcy, Launches New Menopause Program

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |